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Abstract
Background: Obesity is commonly associated with diabetes, cardiovascular diseases and cancer. The purpose of
this study was to determinate the effect of a lower dose of fish oil supplementation on insulin sensitivity, lipid
profile, and muscle metabolism in obese rats.
Methods: Monosodium glutamate (MSG) (4 mg/g body weight) was injected in neonatal Wistar male rats. Three-
month-old rats were divided in normal-weight control group (C), coconut fat-treated normal weight group (CO),
fish oil-treated normal weight group (FO), obese control group (Ob), coconut fat-treated obese group (ObCO) and
fish oil-treated obese group (ObFO). Obese insulin-resistant rats were supplemented with fish oil or coconut fat (1
g/kg/day) for 4 weeks. Insulin sensitivity, fasting blood biochemicals parameters, and skeletal muscle glucose
metabolism were analyzed.
Results: Obese animals (Ob) presented higher Index Lee and 2.5 fold epididymal and retroperitoneal adipose
tissue than C. Insulin sensitivity test (Kitt) showed that fish oil supplementation was able to maintain insulin
sensitivity of obese rats (ObFO) similar to C. There were no changes in glucose and HDL-cholesterol levels amongst
groups. Yet, ObFO revealed lower levels of total cholesterol (TC; 30%) and triacylglycerol (TG; 33%) compared to
Ob. Finally, since exposed to insulin, ObFO skeletal muscle revealed an increase of 10% in lactate production, 38%
in glycogen synthesis and 39% in oxidation of glucose compared to Ob.
Conclusions: Low dose of fish oil supplementation (1 g/kg/day) was able to reduce TC and TG levels, in addition
to improved systemic and muscle insulin sensitivity. These results lend credence to the benefits of n-3 fatty acids
upon the deleterious effects of insulin resistance mechanisms.
Background
The number of obese adults and children around the
world has grown dramatically in the past years. This is a
major concern for public health, since, obesity is com-
monly associated to other conditions such as cardiovas-
cular disease (CVD), type 2 diabetes and some types of
cancer [1]. Physical inactivity and high-fat diets [2], may
be considered the main causes for the increased inci-
dence of overweight and obesity. In fact, obesity has
been strongly associated with metabolic syndrome (MS),
which refers to a clustering of CVD risk factors includ-
ing insulin resistance, type 2 diabetes, dyslipidaemia and
hypertension [3].
The obesity model induced by monosodium glutamate
(MSG) has demonstrated some of the clinical features
observed in individuals with MS [4]. The monosodium
glutamate injected subcutaneously in neonatal period
causes hypothalamic damage [5], and as a consequence,
these animals present several neuroendocrine and meta-
bolic alterations, which leads to higher levels of adipose
tissue accumulation, insulin resistance and hyperinsuli-
nemia [6]. So the use of this model may add new
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ments for both obesity and risk factor for CVD com-
monly observed in MS.
Polyunsaturated fatty acids such as n-6 is largely avail-
able in high-fat diets, and epidemiological studies have
shown that increased ratio of n-6 to n-3 fatty acids in
diet has been proportionally related to increased inci-
dence of type 2 diabetes, CVD, and inflammatory dis-
eases [7,8]. Yet, recent evidence has also linked intake of
saturated fats (i.e. coconut fat), with development of
obesity [9]. Conversely, dietary intake of fish oil, which
presents high amounts of n-3 fatty acids such as eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid
(DHA), has presented beneficial effects on diabetes and
obesity [10]. Several studies have examined the effects of
n-3 PUFA on the prevention of insulin resistance
[11,12], however, few data have shown improvement in
insulin resistance conditions owing to dietary fish intake
[13]. In addition, the concentration of fish oil used in
most studies are high (7 wt% or more) and further
future studies are important to determine the efficacy of
lower concentrations of fish oil. Although the effects of
fish oil supplementation on insulin resistance and dysli-
pidemia have been previously reported, results in this
area are still inconclusive. Therefore, the aim of this
study was to investigate the effects of lower concentra-
tion of fish oil supplementation on fasting lipid profile,
insulin resistance and skeletal muscle glucose metabo-
lism of obese rats induced by monosodium glutamate.
Results
Obesity parameters and insulin sensitivity
Table 1 summarizes the lipid profile from standard diet
and oils. These results confirm the high amounts of n-3
polyunsaturated fatty acids EPA and DHA on fish oil,
while the coconut fat has presented mainly saturated fatty
acids (lauric, myristic and palmitic). Table 2 summarizes
some of the characteristics of the MSG model. MSG-
treated rats became obese as confirmed by higher Index
Lee, even without hyperphagia. Table 2 also shows that,
although the obese group did not gain more weight, they
presented higher epididymal and retroperitoneal fat depos-
its, which is a central characteristic of obesity status.
Obese animals with 90 days of age were insulin resis-
tant as confirmed by insulin tolerance test (Kitt) (p <
0.05) (Figure 1A). The fish oil supplementation was able
to reverse this parameter by showing insulin sensitivity
similar to healthy animals (p > 0.05) (Figure 1B).
Lipid profile
No significant difference amongst all groups was found
in glycemy and HDL levels (Figures 2A and 2B). TC
levels were high on Ob group (p < 0.05) (Figure 2C).
Fish oil supplementation reduced TC levels of obese
animals by 30% (p < 0.05; ObFO vs. Ob) while coconut
fat supplementation did not promote any effect. TG
l e v e l sw e r er e d u c e db y3 4 %a n d3 3 %i nt h eo b e s e
(ObFO) and healthy (FO) fish oil supplemented rats
when compared to their respective control groups (Ob
and C) (Figure 2D).
Muscle metabolism
Incubated skeletal muscle from FO group had 15%
higher lactate production when compared to C group (p
< 0.05) (Figure 3A). Coconut fat supplementation did
not alter lactate production by skeletal muscle when
compared to control group (p > 0.05). Insulin stimuli
increased lactate production by 14% on control group
and by 10% on FO group when compared with the
absence of stimulus (p < 0.05). No alteration was
observed in ObCO after added insulin. Interestingly,
only the ObFO group plus insulin presented an increase
of 10% when compared with absence of insulin (p <
0.05). In presence of insulin, C and CO did not alter lac-
tate production when compared with their respective
control groups (p > 0.05).
Table 1 Fatty acid composition of diet and oils
Fatty acids (g/100 g of total fatty acids) Standard Diet Fish Oil Coconut Fat
12:0 1.2 ± 0.05 5.8 ± 0.6 30.8 ± 1.1
14:0 - - 16.1 ± 0.2
16:0 22.24 ± 2.6 20.9 ± 1.3 48.9 ± 1.1
16:1 n-7 - - -
18:0 3.1 ± 0.3 1.8 ± 0.3 1.9 ± 0.2
18:1 n-9 17.3 ± 0.4 9.1 ± 0.5 7.9 ± 0.2
18:2n-6 51.6 ± 2.4 2.4 ± 0.6 2.0 ± 0.2
18:3n-3 5.3 ± 0.5 - 0.9 ± 0.01
20:4n-6 0.2 ± 0.05 9.7 ± 0.1 -
20:5n-3 0.2 ± 0.04 20.9 ± 1.2 0.7 ± 0.06
22:6n-3 - 26.35 ± 3.1 -
Summary of fatty acids profile of diet and oils.
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synthesis by 50% without insulin stimulus (p < 0.05)
(Figure 3B). In obese group without supplementation
(Ob), the glycogen synthesis was not different when
compared to C group. ObFO presented a 40% increase
in glycogen synthesis when compared to Ob group (p <
0.05). Insulin increased glycogen synthesis by 66% in C
group (p < 0.05). Nevertheless, the basal condition on
glycogen synthesis was high in the FO group and no
additional effect was observed in the presence of insulin
(p > 0.05). In CO plus insulin group, synthesis of glyco-
gen was similar to basal conditions. The Ob group plus
insulin increased the glycogen synthesis by 38% when
compared to basal conditions (p < 0.05). On supplemen-
ted groups (ObFO and ObCO) plus insulin, fish oil and
coconut fat increased by 36% and 45%, respectively,
when compared to absence of stimuli (p < 0.05).
FO increased the glucose oxidation of skeletal muscle
by 42% in basal condition when compared to control
group (p < 0.05) (Figure 3C). CO did not cause any
effect, as well as the obesity condition supplemented or
not (p > 0.05). Insulin increased the glucose oxidation
by 32% on C group when compared to basal condition
(p < 0.05). FO also increased by 31% glucose oxidation
in the presence of insulin (p < 0.05) when compared to
C+I group, while coconut fat supplementation did not
cause any effect. In Ob group plus insulin, glucose oxi-
dation was increased by 45% when compared to basal
conditions (p < 0.05). ObFO plus insulin also increased
by 71% when compared to basal conditions (p < 0.05).
Discussion
The obese animals presented higher Lee index and
increase of fat depots (Table 2). These results confirm
the obesity induction by glutamate monosodium and cor-
roborate previous studies [14,15]. Several metabolic
changes of this model occur due to hypothalamic lesions,
mainly on the arcuate nucleus [16]. These lesions result
in impaired insulin signaling and reduction of GHRH
(Growth Hormone Releasing Hormone), which is asso-
ciated with body length reduction also related to reduc-
tion of body weight (Table 2). This model also presents
reduction of sympathetic activity and low HSL (Hormone
Senstive Lipase) activity which is an enzyme with a role
in the triacyglycerol hydrolysis [17]. These alterations in
adipose tissue metabolism may explain the high quanti-
ties found in epididymal and retroperitoneal adipose tis-
sues (Table 2). Thus, the MSG rats have been used for
studies of obesity because they usually present insulin
resistance and high depots of fat [17-21]. Interestingly,
there are no reports on employing this model to examine
the effects of fish oil supplementation.
Rats fed under an isocaloric high fat diet plus 7% of fish
oil showed improved insulin sensitivity quantified by eugly-
cemic-hyperinsulinemic glucose clamp [22]. Andersen and
Table 2 Morphometric parameters
Group Lee index Weight (g) Food consumption (g/100 g) Epididymal AT (g/100 g) Retroperitoneal AT (g/100 g)
C 314.00 ± 2.89 367.50 ± 7.50 7.27 ± 0.11 0.85 ± 0.06 0.96 ± 0.10
FO 314.7 ± 2.44 371.70 ± 6.70 7.03 ± 0.11 1.00 ± 0.05 1.10 ± 0.07
CO 313.00 ± 2.17 375.00 ± 6.31 7.18 ± 0.15 0.89 ± 0.06 1.02 ± 0.09
Ob 326.60 ± 4.19* 311.00 ± 8.14* 7.16 ± 0.19 2.06 ± 0.15* 2.45 ± 0.12*
ObFO 332.00 ± 3.87 310.00 ± 10.19 6.73 ± 0.16 2.02 ± 0.12 2.50 ± 0.13
ObCO 325.40 ± 2.74 312.90 ± 7.10 6.96 ± 0.18 2.13 ± 0.13 2.70 ± 0.14
Animals with 120 days of age. * when compared to control (C) group
Figure 1 Insulin sensitivity. A. Kitt from animals with 90 days of
age. B. Kitt from animals with 120 days of age. * when compared to
C group; # when compared with Ob group.
Figure 2 Biochemical plasma parameters.A .G l u c o s e ;B .H D L-
cholesterol; C. Total cholesterol; D. Triacylglycerol. * when compared
with C group; # when compared with Ob group.
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insulin sensitivity by HOMA test after oral supplementa-
tion of EPA or DHA (0.5 g/kg) for 8 weeks [12]. Our study
corroborates these previous finding, showing the ability of
fish oil supplementation to improve insulin sensitivity in
obese animals. In contrast, Gillam and coworkers did not
find any effect of the fish oil (10%) added to diet on insulin
resistance, pancreatic function and glucose metabolism
[23]. The discrepancy between these results may be due
the concentration of fish oil added to diet and models
used, i.e., high fat and/or high-sucrose diets to induce obe-
sity, or genetically obesity models.
Dyslipidaemia is a common feature in diabetic people
and it is strongly associated with the development of
atherosclerosis [24]. The MSG rats presented higher
levels of TG and cholesterol, as previously described
[21]. Lipoproteins rich in TG play a role in inflamma-
tory process through NF-B activation [25]. Thus, the
reduction of TG levels found within this study and
others [26,27] is an important factor which might
explain part of the beneficial effects of n-3 fatty acids on
cardiovascular diseases. Hypercholesterolemia increases
the expression of adhesion molecules involved in athero-
genesis [28]. Our study also showed the ability of fish oil
to reduce cholesterol levels of obese rats.
Skeletal muscle is the principal site of glucose metabo-
lism and represents 40 to 50% of the total body mass.
Nevertheless, to best of our knowledge, there is no report
about the changes on muscle metabolism of the MSG
rats. Analyzing the results from muscle metabolism
responses and comparing them to systemic insulin resis-
tance, data might seem paradoxal. There are possible rea-
sons for these findings. First, the results from systemic
insulin resistance may be influenced by several factors,
besides the muscle, such as free fatty acids [29], cytokines
[30] and other insulin targets like adipose tissue and liver
[31]. Second, a state of hyperinsulinemia usually found in
this model could result in the increase of cell metabolism
f o ras h o r tp e r i o d[ 3 2 ] .D ’Alessandro and coworkers
showed that fed rats with a diet plus 7% fish oil increased
insulin sensitivity of skeletal muscle [33]. This study also
found that under insulin stimuli, the glycolytic pathway
was more activated rather than oxidation and storage
components of glucose metabolism. This result differs
from the data herein reported, probably owing to differ-
ent deployed methodologies i.e. muscle type and enzymes
analyzed. Interestingly, our study is the first to report
these effects using a lower dose (1 g/kg/day) orally admi-
nistrated on obese rats induced by MSG.
Conclusions
In conclusion, fish oil supplementation was able to
reduce triacylglycerols and cholesterol levels, in addition
to improvement in systemic and muscle insulin sensitiv-
ity. These results show that n-3 fatty acids might have
crucial role in preventing and reversing insulin restance.
Methods
Materials
All enzymes and reagents for buffers were obtained
from Sigma Chemical (St. Louis, MO). Fish oil was pur-
chased from Herbarium (Parana, Brazil), coconut fat
Figure 3 Muscle metabolism. A. Lactate production by skeletal
muscle incubated; B. Glycogen synthesis from incubated skeletal
muscle; C. Glucose oxidation from skeletal muscle incubated. 100%
was considered as the median of the values obtained in control
group. * when compared with their respective control group; #
when compared with the respective group without stimuli.
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(Nuvilab CR-1) diet from Nuvital Nutrientes (Curitiba,
Brazil). Macronutrients of standard chow presented
63.4% carbohydrates, 25.6% of proteins and 11% of
lipids. Fatty acid composition of the oils and chow was
determined by high-performance liquid chromatogra-
pher as described previously [34]. Briefly, total lipids
were extracted from oils and chow using chloroform-
methanol (2:1 vol/vol) according to Folch et al. [35] and
free fatty acids were obtained by saponification. Fatty
acids were than derivatized with 4-bromomethyl-7-cou-
marin and then separated by high performance liquid
chromatograph (Varian ProStar) using an octadecylsilica
c o l u m n( 2 5c m×4 ,6m mi . d . ;p a r t i c l es i z e5m m ) .
Fatty acids were resolved isocratically using a mobile
phase of acetonitrile-water (gradient from 77:23 to 90:10
vol/vol) and fatty acid derivatives were detected by
fluorescence (325-nm excitation; 395-nm emission).
Animal model and supplementation
Wistar rats were provided by the Experimental Breeding
Center of the Federal University of Parana. All animal
procedures were approved by the Ethical Committee of
Animal Research, Sector of Biological Sciences, Federal
University of Parana. Monosodium glutamate (MSG) (4
mg/g body weight) was subcutaneously injected during
the first 5 days after birth. Control animals received
equimolar solution of saline. On the 21
st day, animals
were weaned and housed under control conditions, in a
12-h light-dark inverted cycle (10 am. to 10 pm.) and 22
± 2°C temperature. Water and standard chow were sup-
plied ad libitum. At 90 days of age, animals were
anesthetized with penthobarbital (50 mg/kg) followed by
intravenous insulin test to confirm insulin resistance.
After, groups were divided in control (C), fish oil sup-
plemented (FO), coconut fat supplemented (CO), obese
(Ob), obese fish oil supplemented (ObFO) and obese
coconut fat supplemented (ObCO). Supplemented
groups received oral administration provided as a single
bolus daily using a micropipette of fish oil or coconut
fat (1 g/kg/day) for 4 weeks.
Body weight and food intake were recorded every
other day. At the end of the supplementation period,
another intravenous insulin test was performed. After an
overnight fasting, animals were anesthetized and killed
by decapitation. After centrifugation, plasma samples
were assayed for analysis of plasma biochemicals. Tissue
samples were collected and kept at -80°C for subsequent
analysis.
Index Lee
T h ei n d e xL e e[ b o d yw e i g h t( g )
1/3 by the naso-anal
length (cm) × 1000] was used as a parameter to evaluate
the degree of obesity [36]
Insulin tolerance test
For estimation of in vivo insulin sensitivity, insulin was
injected intravenously (0.75 U/kg body weight) in 12 h-
fasted obese and non-obese rats. Afterwards, tail blood
samples were collected at 0, 4, 8, 12 and 16 minutes.
The rate for blood glucose disappearance was calculated
based on the linear regression of the blood glucose con-
centrations obtained from 0 to 16 min of the test [37].
Analysis of biochemical plasma parameters
Enzymatic colorimetric assay kits adapted for a micro-
plate reader (Infinite 200 TECAN) were used to deter-
mine fasting plasma glucose, triacylglycerol and total
cholesterol. Enzyme immunoassay kit (SPI-Bio Bertin
Pharma, Montigny le Bretonneux, France) was used to
measure fasting plasma insulin.
Lactate production by incubated tissue
Under penthobarbital anesthesia (50 mg/kg), rats were
killed by cervical dislocation, and soleus muscles were
isolated, split longitudinally in portions weighing 20 to
30 mg. The muscles were preincubated in a water-
bath, gently agitated, for 30 min at 37°C in Krebs-
Ringer (KR) bicarbonate buffer, pH 7.4, pregassed for
30 min with 95% O2 -5 %C O 2, containing 5.6 mM
glucose and 1% BSA. After preincubation, muscles
were transferred to the same buffer under similar con-
ditions for 1 hour, in the absence or presence of 10
mU/mL insulin. At the end of incubation period, lac-
tate from the medium was determined as previously
described [38].
D-[U-
14C] glucose incorporation to glycogen and
oxidation to CO2 by incubated skeletal muscle
F o l l o w i n gt h es a m ei n c u b a t ion procedures, muscles
were transferred to other vials containing the same
buffer, but added 0.3 Ci/mL D-[U-
14C] glucose. One
hour incubation was performed in the absence or pre-
sence of insulin (10 mU/mL) to the KR buffer, mus-
cles were digested in KOH solution and glycogen
synthesis determined as previously described. Pheny-
lethylamine, diluted 1:1 v/v in methanol, was added
into a separate compartment for
14CO2 adsortion and
D-[U-
14C] glucose oxidation. [
14C]-glycogen synthesis
(estimated by [D-
14C]-glucose incorporation into gly-
cogen) was determined as described by Espinal et al
[39].
Statistical Analysis
Data was tested for normal distribution with D’Agos-
tino-Pearson test and differences between groups were
analysed using unpaired t-test and one-way analysis of
variance (ANOVA) followed by post hoc Tukey test. A
value of p < 0.05 was taken to indicate statistical
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expressed as the mean ± standard error mean (SEM).
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